It was hardly a rebound, but Aveo Pharmaceuticals Inc. gained some ground Wednesday, a day after its stock plummeted 31.3 percent as the Food and Drug Administration said it may require another clinical trial of the Cambridge company’s drug for advanced renal cell carcinoma, tivozanib. The FDA had been scheduled to decide by July 28 whether to approve the drug but raised questions about whether it improves survival rates more than a drug that’s already available.
Aveo stock rebounds a bit after big plunge
May 02, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢